Juan Jesús Gómez‐reino
#158,588
Most Influential Person Now
Juan Jesús Gómez‐reino's AcademicInfluence.com Rankings
Juan Jesús Gómez‐reinophilosophy Degrees
Philosophy
#9052
World Rank
#12549
Historical Rank
Logic
#6053
World Rank
#7533
Historical Rank
Download Badge
Philosophy
Juan Jesús Gómez‐reino's Degrees
- PhD Rheumatology Complutense University of Madrid
- Doctorate Medicine University of Barcelona
Why Is Juan Jesús Gómez‐reino Influential?
(Suggest an Edit or Addition)Juan Jesús Gómez‐reino's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Treating rheumatoid arthritis to target: recommendations of an international task force (2010) (1927)
- Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. (2003) (1038)
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis (2010) (844)
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. (2008) (840)
- Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. (2005) (681)
- Adipokines as emerging mediators of immune response and inflammation (2007) (585)
- Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. (2009) (582)
- Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis (2006) (537)
- Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. (2007) (430)
- Leptin, from fat to inflammation: old questions and new insights (2005) (410)
- Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor (2014) (398)
- The emerging role of adipokines as mediators of inflammation and immune responses. (2007) (384)
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. (2012) (336)
- Leptin in the interplay of inflammation, metabolism and immune system disorders (2017) (328)
- Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period (2006) (305)
- What's new in our understanding of the role of adipokines in rheumatic diseases? (2011) (291)
- A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. (2008) (270)
- Towards a pro-inflammatory and immunomodulatory emerging role of leptin. (2006) (249)
- All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists (2007) (243)
- Adipokines as novel modulators of lipid metabolism. (2009) (210)
- Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER (2006) (208)
- Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. (2009) (203)
- Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. (2012) (195)
- Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. (2011) (188)
- Leptin beyond body weight regulation--current concepts concerning its role in immune function and inflammation. (2008) (185)
- Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials (2015) (174)
- Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis (2015) (172)
- The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases (2015) (169)
- An SNP in the 5'-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. (2007) (163)
- The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis (2015) (163)
- Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. (1999) (152)
- Replication of recently identified systemic lupus erythematosus genetic associations: a case–control study (2009) (152)
- Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. (2015) (149)
- Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials (2016) (149)
- Adipokines, Metabolic Syndrome and Rheumatic Diseases (2014) (148)
- Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action (2003) (146)
- Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial (2012) (145)
- Patient Perceptions concerning Pain Management in the Treatment of Rheumatoid Arthritis (2010) (143)
- Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. (2013) (139)
- Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. (2014) (131)
- Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study (2010) (131)
- Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific effects. (2004) (131)
- Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes (2011) (120)
- Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions (2012) (120)
- Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study (2011) (119)
- Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis (2015) (117)
- New Sequence Variants in HLA Class II/III Region Associated with Susceptibility to Knee Osteoarthritis Identified by Genome-Wide Association Study (2010) (114)
- Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists (2010) (108)
- An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage (2007) (108)
- Adipokines and Osteoarthritis: Novel Molecules Involved in the Pathogenesis and Progression of Disease (2011) (105)
- The endogenous growth hormone secretagogue (ghrelin) is synthesized and secreted by chondrocytes. (2005) (104)
- Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. (2008) (102)
- Adipokines in the skeleton: influence on cartilage function and joint degenerative diseases. (2009) (101)
- Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement (2012) (101)
- Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate (2015) (100)
- Cancer in patients with rheumatic diseases exposed to TNF antagonists. (2011) (98)
- Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. (1996) (98)
- Effect of oleocanthal and its derivatives on inflammatory response induced by lipopolysaccharide in a murine chondrocyte cell line. (2010) (94)
- Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. (1994) (94)
- Leptin: a metabolic hormone that functions like a proinflammatory adipokine. (2006) (93)
- Chronic inflammation modulates ghrelin levels in humans and rats. (2003) (89)
- Adiponectin and Leptin Induce VCAM-1 Expression in Human and Murine Chondrocytes (2012) (87)
- Magnetic resonance imaging of the brain in systemic lupus erythematosus. (1995) (86)
- Nontropical pyomyositis in adults. (1994) (85)
- Adiponectin and leptin increase IL-8 production in human chondrocytes (2011) (84)
- Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis (2015) (83)
- Male lupus: retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. (1989) (83)
- Further evidence for the anti-inflammatory activity of oleocanthal: inhibition of MIP-1α and IL-6 in J774 macrophages and in ATDC5 chondrocytes. (2012) (82)
- Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. (2013) (81)
- Reference genes for normalization of gene expression studies in human osteoarthritic articular cartilage (2008) (81)
- At the crossroad between immunity and metabolism: focus on leptin (2010) (80)
- Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis (2003) (80)
- Adiponectin and leptin: new targets in inflammation. (2014) (78)
- Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis (1999) (75)
- Beyond Fat Mass: Exploring the Role of Adipokines in Rheumatic Diseases (2011) (75)
- Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. (2011) (74)
- Survival analysis of 306 European Spanish patients with systemic lupus erythematosus (1998) (74)
- Lack of association of a variable number of aspartic acid residues in the asporin gene with osteoarthritis susceptibility: case-control studies in Spanish Caucasians (2006) (74)
- 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. (2015) (74)
- Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study (2012) (73)
- Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. (2011) (73)
- Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0 (2011) (72)
- Role of Adipokines in Atherosclerosis: Interferences with Cardiovascular Complications in Rheumatic Diseases (2012) (72)
- Opposed independent effects and epistasis in the complex association of IRF5 to SLE (2007) (70)
- Role of European mitochondrial DNA haplogroups in the prevalence of hip osteoarthritis in Galicia, Northern Spain (2009) (70)
- Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. (2017) (69)
- CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial (2010) (68)
- Association of a nsSNP in ADAMTS14 to some osteoarthritis phenotypes. (2009) (68)
- Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors. (2009) (66)
- A Comparison between Septic Bursitis caused by Staphylococcus aureus and those caused by other Organisms (2001) (65)
- Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility (2009) (65)
- Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies (2020) (64)
- Further evidence of the role of frizzled-related protein gene polymorphisms in osteoarthritis (2007) (61)
- High Sodium Intake Is Associated With Self-Reported Rheumatoid Arthritis: A Cross Sectional and Case Control Analysis Within the SUN Cohort (2015) (61)
- Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis (2013) (60)
- Differential expression of adipokines in infrapatellar fat pad (IPFP) and synovium of osteoarthritis patients and healthy individuals (2013) (60)
- Adipokines as drug targets in joint and bone disease. (2014) (58)
- Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations. (2009) (58)
- Outcome of silent lupus nephritis. (1996) (57)
- Oleocanthal inhibits proliferation and MIP-1α expression in human multiple myeloma cells. (2013) (56)
- A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus. (2004) (55)
- Association of a non-synonymous single-nucleotide polymorphism of DNASEI with SLE susceptibility. (2006) (54)
- Adipokines: novel players in rheumatic diseases. (2013) (53)
- Clonally expanded lymphocytes in the minor salivary glands of Sjögren's syndrome patients without lymphoproliferative disease. (1994) (51)
- Akt activity protects rheumatoid synovial fibroblasts from Fas-induced apoptosis by inhibition of Bid cleavage (2010) (51)
- Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/interferon-gamma synergistic NOS type II induction in chondrocytes. (2007) (51)
- Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. (2012) (51)
- Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. (1998) (50)
- Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. (2012) (50)
- Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab (2012) (50)
- The risk of tuberculosis in patients treated with TNF antagonists (2011) (49)
- Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. (2011) (49)
- Invasive aspergillosis in systemic lupus erythematosus. (1995) (48)
- Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model (2010) (48)
- Successful intrauterine therapy with dexamethasone for fetal myocarditis and heart block in a woman with systemic lupus erythematosus. (1993) (48)
- Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial (2012) (47)
- Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis (2013) (47)
- Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease. (2003) (47)
- Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. (1995) (47)
- An update on leptin as immunomodulator (2014) (46)
- Expression and modulation of ghrelin O-acyltransferase in cultured chondrocytes. (2009) (45)
- Polymorphism of the heat-shock protein gene HSP70-2 in systemic lupus erythematosus. (1995) (44)
- Genetic variation in the nuclear factor κB pathway in relation to susceptibility to rheumatoid arthritis (2008) (44)
- Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. (2011) (43)
- Bias in association studies of systemic lupus erythematosus susceptibility due to geographical variation in the frequency of a programmed cell death 1 polymorphism across Europe (2007) (43)
- NUCB2/nesfatin‐1: A new adipokine expressed in human and murine chondrocytes with pro‐inflammatory properties, an in vitro study (2014) (42)
- Particular association of clinical and genetic features with autoimmunity to citrullinated α-enolase in rheumatoid arthritis. (2011) (41)
- Differential upregulation of the three transforming growth factor beta isoforms in human osteoarthritic cartilage (2008) (41)
- Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study (2010) (41)
- Common variations in estrogen-related genes are associated with severe large-joint osteoarthritis: a multicenter genetic and functional study. (2010) (41)
- Choosing the right chondrocyte cell line: Focus on nitric oxide (2015) (40)
- Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies (2018) (39)
- Polymorphism of the interleukin-1 receptor antagonist gene: a factor in susceptibility to rheumatoid arthritis in a Spanish population. (2005) (39)
- Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study (2005) (39)
- Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis. (2008) (38)
- A broad analysis of IL1 polymorphism and rheumatoid arthritis. (2008) (38)
- Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. (2011) (37)
- Apoptosis and Proliferation of Fibroblasts During Postnatal Skin Development and Scleroderma in the Tight-skin Mouse (1997) (36)
- Specific premature epigenetic aging of cartilage in osteoarthritis (2016) (36)
- SERPINE2 Inhibits IL-1α-Induced MMP-13 Expression in Human Chondrocytes: Involvement of ERK/NF-κB/AP-1 Pathways (2015) (36)
- The three most common CARD15 mutations associated with Crohn's disease and the chromosome 16 susceptibility locus for systemic lupus erythematosus. (2003) (35)
- Anti-Carbamylated Protein Antibodies as a Reproducible Independent Type of Rheumatoid Arthritis Autoantibodies (2016) (35)
- Predictors of treatment failure and mortality in native septic arthritis (2015) (35)
- Salmonellosis and systemic lupus erythematosus. Report of ten cases. (1994) (35)
- Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review (2016) (35)
- Lysophosphatidic acid receptor 1 suppression sensitizes rheumatoid fibroblast-like synoviocytes to tumor necrosis factor-induced apoptosis. (2012) (35)
- Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study (2017) (34)
- Cardiometabolic comorbidities and rheumatic diseases: Focus on the role of fat mass and adipokines (2011) (34)
- Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration (2019) (34)
- Novel DNASE I mutations related to systemic lupus erythematosus. (2004) (34)
- Differential contribution of HLA-DR, DQ, and TAP2 alleles to systemic lupus erythematosus susceptibility in Spanish patients: role of TAP2*01 alleles in Ro autoantibody production (1998) (34)
- Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. (1999) (34)
- Poly(ADP-ribose) polymerase inhibition reduces tumor necrosis factor-induced inflammatory response in rheumatoid synovial fibroblasts (2007) (34)
- Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis. (2012) (33)
- Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice (2005) (33)
- Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study (2012) (32)
- Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. (2014) (31)
- Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis (2014) (31)
- DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists (2009) (31)
- Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. (1994) (30)
- Internuclear ophthalmoplegia in systemic lupus erythematosus. (1998) (30)
- Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. (1995) (29)
- Lack of validation of genetic variants associated with anti–tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis (2014) (28)
- Nitric oxide boosts TLR‐4 mediated lipocalin 2 expression in chondrocytes (2013) (28)
- Toxic epidemic syndrome: musculoskeletal manifestations. (1984) (28)
- Adipokines induce pro‐inflammatory factors in activated Cd4+ T cells from osteoarthritis patient (2017) (28)
- Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies. (2014) (27)
- Variants Within STAT Genes Reveal Association with Anticitrullinated Protein Antibody-negative Rheumatoid Arthritis in 2 European Populations (2012) (27)
- Deep sequencing of GDF5 reveals the absence of rare variants at this important osteoarthritis susceptibility locus. (2011) (27)
- New drugs from ancient natural foods. Oleocanthal, the natural occurring spicy compound of olive oil: a brief history. (2015) (26)
- Non-dioxin-like polychlorinated biphenyls (PCB 101, PCB 153 and PCB 180) induce chondrocyte cell death through multiple pathways. (2015) (26)
- Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis (2014) (26)
- C-reactive protein (CRP) levels in systemic lupus erythematosus (SLE) (2005) (25)
- Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies (2018) (25)
- Identification of Novel Adipokines in the Joint. Differential Expression in Healthy and Osteoarthritis Tissues (2015) (25)
- Ghrelin, the same peptide for different functions: player or bystander? (2005) (25)
- SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. (2013) (25)
- FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. (2015) (24)
- Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry (2018) (23)
- Association of anti-citrullinated vimentin and anti-citrullinated α-enolase antibodies with subsets of rheumatoid arthritis. (2012) (23)
- Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience (2014) (22)
- Osteoporosis in Rheumatoid Arthritis (1963) (22)
- Both HLA class II and class III DNA polymorphisms are linked to juvenile rheumatoid arthritis susceptibility. (1990) (21)
- Leptin in joint and bone diseases: new insights. (2013) (20)
- Immune System Disorders Associated with Adulterated Cooking Oil (1987) (20)
- FREQUENCIES OF HLA‐A24 AND HLA‐DR4‐DQ8 ARE INCREASED AND THAT OF HLA‐B BLANK IS DECREASED IN CHRONIC TOXIC OIL SYNDROME (1996) (20)
- CARD15/NOD2 analysis in rheumatoid arthritis susceptibility. (2003) (20)
- Immunogenetics of systemic lupus erythematosus in Spanish patients: differential HLA markers. (1991) (20)
- Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis (2021) (20)
- Familial chondrocalcinosis in the Spanish population. (1986) (19)
- Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study (2016) (19)
- Prospective study of serum and urinary nitrate levels in patients with systemic lupus erythematosus. (1998) (19)
- 12-year followup study of epidemic Spanish toxic oil syndrome. (1995) (19)
- Health-related quality of life in psoriatic arthritis patients in Spain. (2014) (18)
- Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients (2017) (18)
- Association of Systemic Lupus Erythematosus Clinical Features with European Population Genetic Substructure (2011) (17)
- DR, C4, and Bf allotypes in juvenile rheumatoid arthritis. (1984) (17)
- Lack of Association with Rheumatoid Arthritis of Selected Polymorphisms in 4 Candidate Genes: CFH, CD209, Eotaxin-3, and MHC2TA (2009) (17)
- Visfatin as a therapeutic target for rheumatoid arthritis (2019) (17)
- Worsening of obstructive sleep apnoeas in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor. (2004) (17)
- 217. Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1) (2015) (17)
- Analysis of the functional relevance of a putative regulatory SNP of PDCD1, PD1.3, associated with systemic lupus erythematosus (2008) (16)
- Abatacept for the treatment of rheumatoid arthritis (2019) (16)
- Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept (2019) (16)
- Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis (2018) (16)
- Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes (2007) (16)
- Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists. (2006) (16)
- Study of DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility (2006) (16)
- Respiratory chain enzyme defects in patients with idiopathic inflammatory myopathy. (1995) (16)
- Ultrasonographic Assessment of Enthesitis in HLA-B27 Positive Patients with Rheumatoid Arthritis, a Matched Case-Only Study (2013) (15)
- Pseudoaneurysm of the popliteal artery as a complication of an osteochondroma (1979) (15)
- Testing the druggable endothelial differentiation gene 2 knee osteoarthritis genetic factor for replication in a wide range of sample collections (2008) (14)
- Bone metabolism and adipokines: are there perspectives for bone diseases drug discovery? (2014) (14)
- Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis (2018) (14)
- Fibrogenic growth factors in the eosinophilia-myalgia syndrome and the toxic oil syndrome. (1994) (13)
- Abatacept use in rheumatoid arthritis: evidence review and recommendations. (2013) (13)
- Genetic risk load and age at symptom onset of knee osteoarthritis (2012) (13)
- Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus (2014) (13)
- Specific increase of methylation age in osteoarthritis cartilage (2016) (12)
- The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region (2015) (12)
- Cis-regulation of IRF5 expression is unable to fully account for systemic lupus erythematosus association: analysis of multiple experiments with lymphoblastoid cell lines (2011) (12)
- COLLAGEN ANTIBODIES IN TOXIC OIL DISEASE (1985) (11)
- Spanish transcultural adaptation and validation of the English version of the compliance questionnaire in rheumatology (2018) (11)
- IL-36α: a novel cytokine involved in the catabolic and inflammatory response in chondrocytes (2015) (11)
- 38 LOSS OF METHYLATION IN CPG SITES IN THE NUCLEAR FACTOR KAPPA B (NF-κB) ENHANCER ELEMENTS OF INDUCIBLE NITRIC OXIDE SYNTHASE (INOS) IS RESPONSIBLE OF GENE INDUCTION IN HUMAN ARTICULAR CHONDROCYTES (2011) (11)
- Specific Association of HLA–DRB1*03 With Anti–Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis (2019) (11)
- Basic Aspects of Adipokines in Bone Metabolism (2015) (10)
- Light, immunofluorescence and electron microscopy renal biopsy findings as predictors of mortality in eighty-five Spanish patients with systemic lupus erythematosus. (1994) (10)
- Association of a BMP5 microsatellite with knee osteoarthritis: case-control study (2012) (10)
- Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study (2015) (10)
- [Clinical and serological manifestations of 307 Spanish patients with systemic lupus erythematosus. Comparison with other ethnic groups]. (1995) (10)
- RENAL INVOLVEMENT IN TOXIC OIL SYNDROME (1982) (10)
- Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials (2020) (10)
- Crystal arthropathy as a complication of septic arthritis. (1981) (10)
- Abnormal carnitine distribution in the muscles of patients with idiopathic inflammatory myopathy. (1996) (9)
- Objectives and methodology of BIOBADASER phase III (2019) (9)
- Poly(ADP-ribose) polymerase suppression protects rheumatoid synovial fibroblasts from Fas-induced apoptosis. (2008) (9)
- Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies (2020) (8)
- An Eco RI polymorphic site in the human complement C4 gene distinguishes juvenile rheumatoid arthritis (JRA) susceptibility-bearing haplotypes. (1989) (8)
- Muscle dysfunction in elderly individuals with hip fracture. (1999) (8)
- Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register (2020) (8)
- Ghrelin plasmatic levels in patients with fibromyalgia (2003) (8)
- Pulmonary hypertension in connective tissue diseases. (1994) (7)
- Objectives and methodology of BIOBADASER phase iii. (2019) (7)
- Apremilast for the treatment of psoriatic arthritis (2015) (7)
- PMS22 A COST-OF-ILLNESS STUDY OF PSORIATIC ARTHRITIS IN SPAIN (2009) (7)
- Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis (2017) (7)
- Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR (2019) (7)
- Antiphospholipid antibodies in patients with eosinophilia myalgia and toxic oil syndrome. (1997) (7)
- Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin. (2009) (7)
- Effect of lysophosphatidic acid receptor inhibition on bone changes in ovariectomized mice (2015) (6)
- A Broad Analysis of IL 1 Polymorphism and Rheumatoid Arthritis (2008) (6)
- Differential contribution of C4 and HLA-DQ genes to systemic lupus erythematosus susceptibility (1993) (6)
- Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: a case-control study (2012) (6)
- Expression of types I, III and IV collagen genes in fibrotic skin and nerve lesions of toxic oil syndrome patients (1993) (6)
- Infections in patients with rheumatic diseases treated with TNF antagonists. (2012) (6)
- Consensus on the use of Rituximab in Rheumatoid Arthritis. A document with evidence based recommendations (2011) (6)
- Chronic juvenile toxic epidemic syndrome. (1985) (6)
- The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs. (2019) (6)
- Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: case–control study (2014) (6)
- Autoantibodies in sera from patients with L-tryptophan-associated eosinophilia-myalgia syndrome. Demonstration of unique antigen-antibody specificities. (1995) (6)
- Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin (2009) (5)
- Bf polymorphisms in systemic lupus erythematosus patients of Spanish descent. (1986) (5)
- The most reliable probe position in the ultrasonographic examination of the wrist in rheumatoid arthritis. (2012) (5)
- Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain (2021) (5)
- Predictors of response to TNF antagonists. (2014) (5)
- Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER (2018) (5)
- The JAK inhibitor tofacitinib for active rheumatoid arthritis: results from Phase III trials (2013) (4)
- Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis (2020) (4)
- INMUNE-MEDIATED INFLAMMATORY RHEUMATIC diseases in transgender PEOPLE: A scoping review (2021) (4)
- 217. Long-Term 52-Week Results of Palace 1, A Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase Inhibitor, In atients with Psoriatic Arthritis (2014) (4)
- SUMO4 and MAP3K7IP2 single nucleotide polymorphisms and susceptibility to rheumatoid arthritis. (2006) (4)
- Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: three centers experience. (2013) (4)
- Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs. (2019) (4)
- Status of Rheumatology in Spain in 2017: 2.0 Rheumatologists per 100,000 Population. (2018) (4)
- Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry (2021) (4)
- Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain. (2015) (3)
- Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach (2013) (3)
- Correction to: Spanish transcultural adaptation and validation of the English version of the compliance questionnaire in rheumatology (2018) (3)
- THU0204 The Positive Effect of Stringent Criteria for Purified Protein Derivation (PPD) Skin Test on Patients Treated with Certolizumab Pegol (2013) (3)
- 83 ANALYSIS OF CANDIDATE OSTEOARTHRITIS GENES IN A META-ANALYSIS OF 8 GENOME-WIDE ASSOCIATION STUDIES (2011) (3)
- Toxic oil syndrome and eosinophilia myalgia syndrome: similar, different or the same disorder? (1994) (3)
- Expression and modulation of adipolin/C1qdc2: a novel adipokine in human and murine ATDC-5 chondrocyte cell line (2012) (3)
- FRI0029 Nucb2/nesfatin-1: a new adipokine expressed in human and murine chondrocytes with pro-inflammatory properties (2013) (3)
- O03 Apremilast, an Oral Phosphodiesterase-4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials (2016) (2)
- Long-term therapy for rheumatoid arthritis (1996) (2)
- Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis. (2020) (2)
- Practical normalization of mRNA expression in quantitative PCR for cartilage research. (2009) (2)
- SAT0317 Tofacitinib in patients with psoriatic arthritis and metabolic syndrome: a post-hoc analysis of phase 3 studies (2018) (2)
- Mortality rate is reduced in ra patients treated with TNF antagonists. Data from biobadaser (2006) (2)
- Cis-regulation of IRF 5 expression is unable to fully account for systemic lupus erythematosus association : analysis of multiple experiments with lymphoblastoid cell lines (2011) (2)
- IL-36α: a novel cytokine involved in the inflammatory response in human chondrocytes (2014) (2)
- Factor B activation in systemic lupus erythematosus. (1990) (2)
- FRI0389 EFFECTIVENESS OF BIOLOGIC THERAPY ON DISEASE ACTIVITY IN ANKYLOSING SPONDYLITIS: A BIOBADASER III OBSERVATIONAL STUDY (2019) (2)
- Inflammation and HIV infection: a friendly connection (1996) (1)
- High unmet need for arthritis pain management among EU and US rheumatoid arthritis patients despite effective therapies (2008) (1)
- 370 THE mtDNA HAPLOGROUP J IS A PROTECTIVE FACTOR TO HIP AND KNEE OSTEOARTHRITIS (2008) (1)
- Update of the position paper of the Spanish Society of Rheumatology on biosimilar drugs (2020) (1)
- NEW FUNCTIONAL MICROSATELLITE ASSOCIATED WITH OSTEOARTHRITIS SUSCEPTIBILITY (2014) (1)
- DEEP SEQUENCING OF GDF5 IN OVER 1900 OSTEOARTHRITIS CASES AND CONTROLS REVEALS NOVEL AND POTENTIALLY FUNCTIONAL RARE VARIANTS IN THE PROTEIN CODING AND PROMOTER REGIONS OF THE GENE (2010) (1)
- Identification of three new cis-regulatory IRF5 polymorphisms: in vitro studies (2013) (1)
- Ghrelin in the Local Regulation of Endocrine Glands (2006) (1)
- 395 IMPORTANCE OF THE SELECTION OF CONTROLS IN GENETIC STUDIES OF KNEE OSTEOARTHRITIS (2010) (1)
- FRI0290 FACTORS ASSOCIATED WITH PERSISTENCE OF GOLIMUMAB TREATMENT IN THE BIOBADASER REGISTRY, UP TO 7 YEARS OF FOLLOW-UP (2020) (1)
- Adipokines induce inflammatory mediators in CD4+ t cells and modulate the cross talk between CD4+ t lymphocytes and chondrocytes from OA patients. (2014) (1)
- THU0009 Reduced Clinical Improvement in Rheumatoid Arthritis Patients Showing IgG1 Allotype -Infliximab Incompatibility (2013) (0)
- P208 - HLA-A24, HLA-DR4-DQ8 increase and HLA-B blank decrease in chronic Toxic Oil Syndrome (1996) (0)
- [Therapy with corticoid pulses, plasmapheresis, and corticoid pulses combined with plasmapheresis in systemic lupus erythematosus]. (1986) (0)
- SAT0159 CHANGING PATTERN OF THE USE OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS (2019) (0)
- Gene-based analysis of a metaanalysis of osteoarthritis genome wide association studies (2013) (0)
- SAT0002 Specific Premature Epigenetic Aging of Cartilage in Osteoarthritis (2016) (0)
- antagonists rheumatic diseases treated with TNF shingles and chickenpox in patients with Incidence and risk of hospitalisation due to (2010) (0)
- THU0581 Use of biological therapies in adult patients diagnosed with juvenile idiopathic arthritis: results from biobadaser, the spanish registry of adverse events with biologic therapies (2018) (0)
- Efficacy and safety of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis (2014) (0)
- FRI0447 Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from A Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 1) (2016) (0)
- 074. LONG-TERM (UP TO 156 WEEKS) SAFETY PROFILE OF ORAL APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF PALACE 1–3 (2017) (0)
- Durability of apremilast response through 5 years of treatment in subjects with psoriatic arthritis (2018) (0)
- [Does mixed connective tissue disease exist or not?]. (1985) (0)
- 022 FOLLOW-UP ANALYSIS OF THE ROLE OF GENETIC VARIATION IN ADAMTS14 IN OSTEOARTHRITIS SUSCEPTIBILITY (2009) (0)
- 226 DIFFERENTIAL EXPRESSION OF TGF-BETA ISOFORMS IN HUMAN OSTEOARTHRITIC CARTILAGE (2007) (0)
- P242 FURTHER EVIDENCE FOR A ROLE OF FRIZZLED RELATED PROTEIN 3 GENE POLYMORPHISMS IN GENERALIZED OSTEOARTHRITIS SPECIFICALLY IN WOMEN (2006) (0)
- Practice guidelines for the use of subcutaneous abatacept. (2014) (0)
- Potential role of apremilast for the treatment of psoriatic arthritis (2014) (0)
- Adipokines as biomarkers of rheumatic diseases (2012) (0)
- [Recommendations for the management of influenza A (H1N1) in rheumatic patients with immunosuppression]. (2010) (0)
- International Conference on NeuroEndocrine Immunology in Rheumatic Diseases Steroids in NeuroEndrocrine Immunology and Therapy of Rheumatic Diseases (2013) (0)
- Resistin Visfatin Leptin Atherosclerosis Obesity Rheumatoid arthritis Osteoarthritis Diabetes Liver injury Cardiovascular diseases Insulin resistance Rheumatoid arthritis Osteoarthritis Hepatitis Intestinal inflammation Sepsis Encephalomyelitis Obesity Type 2 diabetes ( ? (2016) (0)
- P248 NONSYNONYMOUS POLYMORPHISMS OF THE MAIN IN VIVO AGGRECANASE, A DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN MOTIFS 5, IN SUSCEPTIBILITY TO OSTEOARTHRITIS (2006) (0)
- Analysis of CTLA4 polymorphisms in systemic lupus erythematosus patients from several European populations (2006) (0)
- Separate association with susceptibility or protection to systemic lupus erythematosus of interferon regulatory factor 5 (IRF5) polymorphisms (2007) (0)
- Rheumatology. Inflammation and HIV infection: a friendly connection. (1996) (0)
- Leptin, a railroad switch enabling crossover signals among inflammation, immunity and metabolism (2010) (0)
- Antibodies to extractable cellular antigens in Spanish systemic lupus erythematosus (SLE) patients (1987) (0)
- Adipokines, Molecular Players at the Crossroad Between Inflammation and Oxidative Stress: Role in Arthropathies (2013) (0)
- PMS78 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS (2009) (0)
- Association of allelic variants of the genes coding for aromatase and estrogen receptor with osteoarthritis of the knee (2010) (0)
- SP0114 What’s New: Psoriatic Arthritis (2013) (0)
- AB0005 Association of FCGR2A with response to infliximab in rheumatoid arthritis patients (2013) (0)
- Erratum “Status of Rheumatology in Spain in 2017: 2.0 Rheumatologists per 100,000 Population” [Reumatol Clin. 2018;14(5):311-316] (2018) (0)
- Towards gene-based analysis of genome-wide association osteoarthritis data (2012) (0)
- 359 ASSOCIATION OF REGULATORY POLYMORPHISMS IN MATRIX METALLOPROTEASES WITH OSTEOARTHRITIS RISK (2008) (0)
- University of Groningen Association of Systemic Lupus Erythematosus Clinical Features with European Population Genetic Substructure Alonso-Perez, (2011) (0)
- 186 “EX VIVO” ANALYSIS OF THE FIRST DOWNSTREAM EVENTS OF TGF-β SIGNALING IN HUMAN OSTEOARTHRITIC CARTILAGE (2008) (0)
- Radiographic bone changes in the toxic oil syndrome. (1987) (0)
- AB0827 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS (2020) (0)
- 166 Long-term (156-week) improvements in dactylitis and enthesitis with apremilast inpsoriatic arthritis subjects: analysis of a large, pooled PALACE 1-3 database (2018) (0)
- Environmental pollutants and osteoarthritis: Effects of non-dioxin-like polychlorinated biphenyls on cultured chondrocytes (2014) (0)
- replication in a wide range of sample collections gene 2 knee osteoarthritis genetic factor for Testing the druggable endothelial differentiation (2009) (0)
- Potential role of apremilast (2014) (0)
- THE arcOGEN CONSORTIUM: STAGE 1 OF A GENOME-WIDE ASSOCIATION SCAN FOR OSTEOARTHRITIS (2010) (0)
- Reply: Pathogenic relevance of anti-citrullinated vimentin antibodies: comment on the article by Montes et al. (2013) (0)
- Status of Rheumatology in Spain in 2017: 2.0 Rheumatologists per 100 000 Population (2018) (0)
- AB0239 EFFECT OF SMOKING ON THE EFFICACY OF TNF INHIBITORS IN THE TREATMENT OF CHRONIC INFLAMMATORY IMMUNE-MEDIATED DISEASES: SYSTEMATIC REVIEW AND META-ANALYSIS (2019) (0)
- FRI0013 Ese-1: a novel pro-inflammatory and catabolic factor in articular cartilage (2013) (0)
- 394 EVALUATION OF AGE OF SYMPTOMS ONSET ON THE ASSOCIATION OF SUSCEPTIBILITY LOCI WITH KNEE OSTEOARTHRITIS (2010) (0)
- AB0290 Serum protein biomarkers for response of rheumatoid arthritis to infliximab (2013) (0)
- FRI0146 SURVIVAL OF JAK INHIBITORS: REAL-WORLD DATA FROM THE BIOBADASER III REGISTRY (2019) (0)
- Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases (2020) (0)
- 292 A CHANGE OF GLUTAMIC ACID FOR GLICINE IN THE ADAMTS14 PROTEASE ASSOCIATED WITH SUSCEPTIBILITY TO PRIMARY KNEE OSTEOARTHRITIS (2007) (0)
- A MULTICENTER STUDY OF THE ASSOCIATION OF AROMATASE AND ESTROGEN RECEPTOR GENES WITH HIP AND KNEE OSTEOARTHRITIS (2010) (0)
- Leptin, a new "godfather" in the cytokines super "family" (2006) (0)
- THU0021 DNA Methylation of Peripheral Blood Cell Subpopulations in Patients with Early Rheumatoid Arthritis before and after Methotrexate Treatment (2013) (0)
- Synergistic induction of ELF3. In vitro effect of leptin and IL-1 in human chondrocytes (2012) (0)
This paper list is powered by the following services:
